TScan Therapeutics, Inc. TCRX
0.19 USD +0.01 (+5.53%)
At closeNov 3, 2026, 4:00 PM EST
0.19 0.00 +0.53%
After hours · Nov 3, 4:00 PM ET
0.1768 Day range 0.1954
0.173 52-week range 1.47
- YTD
- -81.10%
- 1 year
- -84.76%
Financial health
Altman Z-Score
-6.19 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 5
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 4
Valuation
P/E -1.0×
FY 2019 5y median -2.2× FY 2025
P/S 12.6×
FY 2019 5y median 12.6× FY 2025
P/B 1.1×
FY 2019 5y median 1.1× FY 2025
P/FCF -0.9×
FY 2019 5y median -1.8× FY 2025
EV/EBITDA -0.6×
FY 2019 5y median -0.6× FY 2025
EV/Sales 6.9×
FY 2019 5y median 6.9× FY 2025
FCF Yield -107.6%
FY 2019 5y median -54.5% FY 2025
Profitability
Gross Margin 72.2%
FY 2019 5y median 100.0% FY 2025
Operating Margin -1315.4%
FY 2019 5y median -492.3% FY 2025
Net Margin -1256.8%
FY 2019 5y median -489.3% FY 2025
ROE -105.4%
FY 2019 5y median -59.1% FY 2025
ROIC -62.5%
FY 2019 5y median -37.5% FY 2025
ROA -56.7%
FY 2019 5y median -33.3% FY 2025
Growth (YoY)
Revenue 266.7%
FY 2019 FY 2025
Operating Income -0.7%
FY 2019 FY 2025
EPS (diluted) 12.3%
FY 2019 FY 2025
Free Cash Flow -21.9%
FY 2019 FY 2025
Financial Health
Current Ratio 8.4×
FY 2019 5y median 7.8× FY 2025
Quick Ratio 8.4×
FY 2019 5y median 7.8× FY 2025
Debt / Equity 0.8×
FY 2019 5y median 0.6× FY 2025
Net Debt / EBITDA 0.5×
FY 2019 5y median 0.6× FY 2025
Interest Coverage -49.0×
FY 2019 5y median -36.9× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31